bb2121 for Multiple Myeloma (KarMMa-4 Trial)

"Patiens can sign up for this trial at Local Institution - 103 in Nashville, Tennessee, Local Institution - 112 in Portland, Oregon and the flagship location of Local Institutioin - 121 situated in New york City. Additionally, there are 42 other sites available to enroll patients."

"The clinical trial listed on ClinicalTrials.gov does not appear to be looking for participants at the moment; it was initially posted in late May 2020 and edited last October 7th 2022. Nevertheless, there are currently 1973 other trials that welcome enrolment of new patients."

"At this time, the trial is no longer recruiting participants. It was first made available on May 27th 2020 and its last update took place on October 7th 2022. If you are curious about other trials for similar treatments, there are 807 clinical studies enrolling patients with multiple myeloma and 1166 actively looking for candidates to test bb2121's efficacy."

"BB2121 is a common choice of treatment for those with chronic lymphocytic leukemia. Additionally, it may be effective against cancer in the lungs and other conditions that have not responded to ≥4 lines of therapy or two prior systemic chemotherapy regimens."

"Since this is an initial clinical trial, there is limited data regarding bb2121's safety and efficacy. As such, the score for its safety was assigned a value of 1 on our scale."

"The clinical trial sponsor, Celgene, has reported that the primary outcome they will measure over a two-year period after the last patient's infusion is dose-limiting toxicity (DLT). Secondary outcomes include overall survival (OS), pharmacokinetics - AUC and time to complete response (TCR)."

"Currently, 1166 research projects are exploring bb2121. Out of those investigations, 217 have progressed to their third phase and 40648 medical centres worldwide are hosting trials for this medication. Notably, Philadelphia is a hub for such studies."